Pharmaceutical - GlaxoSmithKline, Licensing

Filter

Current filters:

GlaxoSmithKlineLicensing

Popular Filters

1 to 25 of 39 results

Codexis leaps on licensing deal with GlaxoSmithKline

Codexis leaps on licensing deal with GlaxoSmithKline

15-07-2014

Codexis, a developer of biocatalysts for the pharmaceutical and fine chemical industries, saw its share…

CodeEvolverCodeEvolver protein engineering platform technologyCodexisGlaxoSmithKlineLicensingPharmaceuticalProductionUK

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

GlaxoSmithKline divests rights to Treximet to Pernix for $250 million

15-05-2014

UK pharma giant GlaxoSmithKline will divest all of its rights to migraine drug Treximet (sumatriptan/naproxen…

GlaxoSmithKlineLicensingNeurologicalPernix TherapeuticsPharmaceuticalPozenTreximetUSA

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

13-01-2014

Santaris Pharma, a Denmark-based clinical-stage biopharma company, has signed an agreement with UK drug…

GlaxoSmithKlineLicensingPharmaceuticalSantaris Pharma

Immunocore makes progress in deal with GSK

Immunocore makes progress in deal with GSK

07-11-2013

UK-based biotech firm Immunocore has achieved its first milestone in its major research and licensing…

EuropeFinancialGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearchUK

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

GlaxoSmithKline returns rights to vercirnon

19-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) says that partner GlaxoSmithKline (LSE: GSK), the UK’s…

ChemoCentryxGastro-intestinalsGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalvercirnon

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Briefs: Eddingpharm deal with GSK China for Tykerb; AEterna Zentaris and Ergomed link on AEZS-108

10-04-2013

Chinese drugmaker Eddingpharm has entered into a collaboration agreement with UK pharma giant GlaxoSmithKline's…

AEterna ZentarisAEZS-108Asia-PacificErgomed Clinical ResarchGlaxoSmithKlineLicensingOncologyPharmaceuticalResearchTykerb

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir

18-02-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline

09-01-2013

BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world's…

AmgenBIND BiosciencesBiotechnologyGlaxoSmithKlineLicensingOncologyPharmaceuticalPriaxon

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

UT MD Anderson signs potentially lucrative deal with GlaxoSmithKline

10-12-2012

The University of Texas MD Anderson Cancer Center, one of the world's leading cancer research and treatment…

GlaxoSmithKlineLicensingOncologyPharmaceuticalResearch

GlaxoSmithKline gives up on XenoPort Horizant collaboration

09-11-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has reached an agreement with US partner XenoPort…

GlaxoSmithKlineHorizantLicensingNeurologicalPharmaceuticalXenoPort

Milestone payments for Epizyme and Antares Pharma

03-10-2012

Privately-held US biotech startup Epizyme says it has received a$4 million in milestone payments from…

Antares PharmaEpizymeFinancialGlaxoSmithKlineLicensingOncologyPfizerPharmaceuticalResearch

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million

11-09-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty…

BenlystaBiogen IdecBiotechnologyFinancialGlaxoSmithKlineHuman Genome SciencesLicensingPharmaceuticalRare diseases

Research news: dolutegravir; TD-1211; and synaptic modulators

11-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

1 to 25 of 39 results

Back to top